51. Escherichia coli ST542 Co-Harbouring blaNDM-1 and mcr-1 in a Pig Farm, China

Abstract:

Carbapenems are potent antibiotics utilized to treat serious infections caused by multidrug-resistant (MDR) Gram-negative bacteria.1 However, the clinical use of carbapenems has led to the emergence and global dissemination of carbapenem-resistant Enterobacteriaceae (CRE), which pose a significant threat to effective clinical therapy.1 The genes encoding carbapenemases, particularly the New Delhi metallo-β-lactamase gene blaNDM, have been widely distributed among humans and detected in animals, food, and the environment.1,2 Colistin is considered as the last therapeutic resort for treating MDR Gram-negative bacteria, especially CRE bacteria.1,3 However, its efficacy has been undermined by the emergence of various antimicrobial resistance mechanisms, such as mutations in the two-component regulatory systems PmrA-PmrB and PhoP-PhoQ.3 Particularly, the global spread of plasmid-mediated colistin resistance gene mcr, first identified in 2015, has further exacerbated this issue.3 Here, we report the recent identification of Escherichia coli ST542 strains co-producing MCR-1 and NDM-1 isolated from a pig farm in Yangzhou, China.

Shao, P. Y., Jiang, Y., Mei, C. Y., Li, W., Wang, Z. Y., Jiao, X., Wang, J.; Sun, L. (2025). Escherichia coli ST542 Co-Harbouring blaNDM-1 and mcr-1 in a Pig Farm, China. Infection and Drug Resistance, 18, 1183–1186. DOI: 10.2147/IDR.S508552.